Sudarshan Sukhani of s2analytics.com told CNBC-TV18, "With every decline, the short selling becomes little more risk prone because Ranbaxy Laboratories is in a free fall. So we cannot even say, okay, it is going to find support here. There is no support. So for somebody who is willing to take some kind of a risk, Ranbaxy Laboratories continues to be a short selling idea."
Also Read: Ranbaxy slumps to near 4-year low; rupee to add to injuryDiscover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
